Our developed AS16‐EL@MPLA/p‐FX nanoparticle overcomes this challenge by effectively recruiting and activating cDC1 at the tumor site, thereby amplifying antigen presentation and strengthening the CD8+ T cell‐mediated immune response. This evidence concerns the gene CD8A and neoplasm.